Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

N.S. Stuart; G. von Minckwitz; I. Chernozemsky; L. Sirakova; P. Chilingirov; R. Souchon; N. Marschner; U. Kleeberg; C. Tsekov; D. Fritze; C.F. Thomssen; N. Stuart; J.B. Vermorken; S. Loibl; K.H. Merkle; M. Kaufmann

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

N.S. Stuart
, G. von Minckwitz
, I. Chernozemsky
, L. Sirakova
, P. Chilingirov
, R. Souchon
, N. Marschner
, U. Kleeberg
, C. Tsekov
, D. Fritze
, C.F. Thomssen
, N. Stuart
, J.B. Vermorken
, S. Loibl
, K.H. Merkle
, M. Kaufmann

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	871-877
Journal	Anti-Cancer Drugs
Volume	16
Issue number	8
Publication status	Published - 1 Sept 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Stuart, N. S., von Minckwitz, G., Chernozemsky, I., Sirakova, L., Chilingirov, P., Souchon, R., Marschner, N., Kleeberg, U., Tsekov, C., Fritze, D., Thomssen, C. F., Stuart, N., Vermorken, J. B., Loibl, S., Merkle, K. H., & Kaufmann, M. (2005). Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anti-Cancer Drugs, 16(8), 871-877.

Stuart, N.S. ; von Minckwitz, G. ; Chernozemsky, I. et al. / Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. In: Anti-Cancer Drugs. 2005 ; Vol. 16, No. 8. pp. 871-877.

@article{7237d35175a848c7815010de6a05146f,

title = "Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC",

author = "N.S. Stuart and \{von Minckwitz\}, G. and I. Chernozemsky and L. Sirakova and P. Chilingirov and R. Souchon and N. Marschner and U. Kleeberg and C. Tsekov and D. Fritze and C.F. Thomssen and N. Stuart and J.B. Vermorken and S. Loibl and K.H. Merkle and M. Kaufmann",

year = "2005",

month = sep,

day = "1",

language = "English",

volume = "16",

pages = "871--877",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

Stuart, NS, von Minckwitz, G, Chernozemsky, I, Sirakova, L, Chilingirov, P, Souchon, R, Marschner, N, Kleeberg, U, Tsekov, C, Fritze, D, Thomssen, CF, Stuart, N, Vermorken, JB, Loibl, S, Merkle, KH & Kaufmann, M 2005, 'Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC', Anti-Cancer Drugs, vol. 16, no. 8, pp. 871-877.

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. / Stuart, N.S.; von Minckwitz, G.; Chernozemsky, I. et al.
In: Anti-Cancer Drugs, Vol. 16, No. 8, 01.09.2005, p. 871-877.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

AU - Stuart, N.S.

AU - von Minckwitz, G.

AU - Chernozemsky, I.

AU - Sirakova, L.

AU - Chilingirov, P.

AU - Souchon, R.

AU - Marschner, N.

AU - Kleeberg, U.

AU - Tsekov, C.

AU - Fritze, D.

AU - Thomssen, C.F.

AU - Stuart, N.

AU - Vermorken, J.B.

AU - Loibl, S.

AU - Merkle, K.H.

AU - Kaufmann, M.

PY - 2005/9/1

Y1 - 2005/9/1

M3 - Article

SN - 0959-4973

VL - 16

SP - 871

EP - 877

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 8

ER -

Stuart NS, von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anti-Cancer Drugs. 2005 Sept 1;16(8):871-877.